Breaking News
They're Using This War To 'Replace The Dollar'
What Schools Don't Teach You About American Indians
Wait what?! Farmers in Missouri & elsewhere have been finding boxes of Ticks?
"The greatest crime against humanity in recorded history… 81% of the women in one section...
Top Tech News
China Introduces Pistol-Like Coil-Gun Based On Electromagnetic-Launch Systems
NEXT STOP: MARS IN JUST 30 DAYS?!
Poland's researchers discovered a bacteria strain that destroys pancreatic cancer.
Intel Partners with Tesla and SpaceX on Terafab
Anthropic Number One AI in Ranking and Revenue - Making $30 Billion Per Year
India's indigenous fast breeder reactor achieves critical stage: PM Modi
Mexico Speeds Up Biometric ID Rollout
Homemade solar drone smashes endurance record with 5+ hours aloft
This Home Flywheel Makes Storing Solar 90% Cheaper -- And It Works Forever!
Physicists captured a crystal made only of electrons, forming a honeycomb pattern without atoms...
Experimental cancer drug that targets common genetic fault can shrink tumours...
An experimental cancer drug that targets a common genetic fault has been shown to shrink tumours by up to 67 per cent in just six weeks.
Scientists tested their newly developed anti-cancer drug AMG 510 on four patients, two of whom saw their tumours shrink. It did not work for the others.
In studies on mice, the treatment helped to shrink, and in some cases eradicate, the growing tumours.
The daily pill works by turning 'off' the KRAS gene. Mutated forms of the genes are permanently trapped 'on', causing cancerous cells to multiply.
This abnormal activity fuels the development of up to 50 per cent of lung cancers, as well as some pancreatic and bowel cancers.
The pharmaceutical company described their findings as a 'milestone' for patients with cancer KRAS-mutant cancers.
The research was led by by pharmaceutical company Amgen Research, based in Thousand Oaks, California.
The findings, published in Nature, are the first to report the effects of inhibiting KRAS with a drug.